In Q4 2025, Balchem generated record net sales of $263617000 and net earnings of $39225000, driven by growth across all three reporting segments. Adjusted EBITDA rose to $67893000 and free cash flow reached $51222000, reflecting strong operational performance.

Balchem delivered strong third-quarter results, driven by market penetration of specialty nutrients and delivery systems, and favorable trends in food and nutrition. The company achieved record net sales of $267.6 million and record adjusted EBITDA of $71.4 million, with growth in sales and earnings from operations across all three reporting segments.

Balchem Corporation reported strong financial results for the fourth quarter of 2024, with record net sales of $240.0 million and adjusted EBITDA of $62.8 million. The company's GAAP net earnings increased by 26.0% compared to the prior year quarter, and free cash flow was $39.8 million.

Balchem Corporation reported strong third quarter financial results with solid revenue growth and record earnings from operations and adjusted EBITDA. Net sales were $239.9 million, net earnings were $33.8 million, adjusted EBITDA was $64.4 million, and free cash flow was $42.2 million.

Balchem Corporation reported a 1.2% increase in net sales to $234.1 million for the second quarter of 2024. GAAP net earnings increased by 6.5% to $32.1 million, with earnings per share at $0.98. Adjusted EBITDA reached a record $62.3 million, a 5.0% increase from the prior year quarter. The Human Nutrition and Health and Specialty Products segments showed strong sales and earnings growth.

Balchem Corporation reported Q4 2023 results with net sales of $228.7 million, net earnings of $26.6 million, adjusted EBITDA of $55.4 million, and free cash flow of $56.0 million. The Human Nutrition and Health segment had record sales and earnings.

Balchem Corporation reported a decrease in net sales but an increase in net earnings and adjusted EBITDA for the third quarter of 2023. The company's Human Nutrition & Health segment achieved record quarterly sales and earnings from operations.

Balchem Corporation reported second quarter net sales of $231.3 million, a decrease of 2.3% compared to the prior year quarter. Net earnings were $30.1 million, an increase of 1.1% from the second quarter 2022. Adjusted EBITDA was a record $59.1 million, an increase of 4.6% from the prior year.

Balchem Corporation reported a 9.1% increase in fourth-quarter net sales, reaching $232.5 million. Adjusted EBITDA rose by 14.6% to $52.3 million, while GAAP net earnings decreased by 14.2% to $21.4 million. The company's adjusted earnings per share increased to $0.94.

Balchem Corporation reported third quarter net sales of $244.3 million, a 23.4% increase compared to the prior year quarter. GAAP net earnings were $25.2 million, resulting in GAAP earnings per share of $0.78. Adjusted EPS was $1.00. The company's growth was supported by sales growth in all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, as well as strategic initiatives such as the acquisition of Bergstrom.

Balchem Corporation reported a strong second quarter in 2022, with record net sales of $236.7 million and net earnings of $29.8 million. The company's performance was driven by growth in all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Balchem also completed the acquisition of Kappa Bioscience AS, expanding its presence in the human nutrition industry.

Balchem Corporation reported record fourth-quarter sales of $213.1 million and net earnings of $24.9 million, with GAAP EPS of $0.76 and adjusted EPS of $0.85. The company experienced growth in all three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.

Balchem Corporation reported record third-quarter results, with net sales reaching $197.9 million and net earnings of $25.0 million. The company's performance reflects the strength of its global market positions and the resilience of its business model in the face of global supply chain disruptions and input cost inflation.

Balchem Corporation reported record second quarter net sales of $202.4 million, a 16.7% increase compared to the prior year quarter. GAAP EPS was $0.70 and adjusted EPS was $0.93. The company experienced a flash flood event at its Verona, Missouri plant, which had a negative direct financial impact of approximately $3.8 million.

Balchem Corporation reported record fourth-quarter sales of $180.7 million, an 8.5% increase year-over-year. Net earnings were $22.2 million, up from $20.4 million in the prior year. GAAP EPS was $0.68, while adjusted EPS reached $0.83. The company experienced sales growth across all three segments.

Balchem Corporation reported record third quarter net sales of $175.1 million and net earnings of $21.6 million. The company's adjusted EBITDA reached an all-time record of $44.4 million.

Balchem Corporation reported record second quarter net sales and earnings, driven by growth across all three reporting segments. The company's strong cash flow allowed for debt repayment and continued investment in growth initiatives.

Balchem Corporation reported fourth quarter net sales of $166.5 million, GAAP EPS of $0.63, and adjusted EPS of $0.88. The company saw sales growth in three of its four segments and record adjusted net earnings.